Pennsylvania Trust Co Sells 2,834 Shares of Novartis AG (NVS)
Pennsylvania Trust Co decreased its position in Novartis AG (NYSE:NVS) by 3.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 81,498 shares of the company’s stock after selling 2,834 shares during the period. Pennsylvania Trust Co’s holdings in Novartis were worth $6,842,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NVS. WFG Advisors LP grew its holdings in shares of Novartis by 38.1% in the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock valued at $102,000 after acquiring an additional 337 shares in the last quarter. Wealthcare Advisory Partners LLC bought a new position in shares of Novartis in the 3rd quarter valued at about $106,000. Cable Hill Partners LLC grew its holdings in shares of Novartis by 588.8% in the 3rd quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock valued at $112,000 after acquiring an additional 1,107 shares in the last quarter. Harding Loevner LP bought a new position in shares of Novartis in the 2nd quarter valued at about $146,000. Finally, Sawyer & Company Inc bought a new position in shares of Novartis in the 4th quarter valued at about $183,000. 10.85% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts have recently weighed in on NVS shares. Barclays cut Novartis from an “equal weight” rating to an “underweight” rating in a report on Wednesday, October 25th. Zacks Investment Research cut Novartis from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Nord/LB reiterated a “neutral” rating on shares of Novartis in a report on Wednesday, December 27th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a report on Tuesday, October 31st. Finally, Leerink Swann lifted their price target on Novartis from $89.00 to $91.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Five investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $85.32.
Novartis AG (NYSE:NVS) opened at $86.73 on Wednesday. Novartis AG has a 1-year low of $69.53 and a 1-year high of $87.29. The company has a current ratio of 1.08, a quick ratio of 0.81 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $204,978.81, a PE ratio of 30.86, a P/E/G ratio of 2.32 and a beta of 0.73.
Novartis (NYSE:NVS) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.29 EPS for the quarter, topping analysts’ consensus estimates of $1.25 by $0.04. Novartis had a return on equity of 15.77% and a net margin of 13.73%. The business had revenue of $12.41 billion during the quarter, compared to analysts’ expectations of $12.21 billion. During the same quarter last year, the company posted $1.23 earnings per share. Novartis’s quarterly revenue was up 2.4% on a year-over-year basis. analysts forecast that Novartis AG will post 4.79 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.watchlistnews.com/pennsylvania-trust-co-sells-2834-shares-of-novartis-ag-nvs/1810418.html.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with Analyst Ratings Network's FREE daily email newsletter.